Tigecycline Treatment of Urinary Tract Infection and Prostatitis: Case Report and Literature Review

Overview

Journal Can J Hosp Pharm

Date 2012 Jul 12

PMID 22783032

Citations 5

Authors

Duane Bates

Mike Parkins

Robin Hellweg

Kimberly Gibson

Jennifer M Bugar

Affiliations

Soon will be listed here.

Citing Articles

Case Report: Management of recurrent UTI with tigecycline in a kidney transplant recipient.

Shettar S, Sumana M, Shetty M, Maheshwarappa Y, Reddy R, Srinivasan A Front Transplant. 2025; 3:1496702.

PMID: 40040669 PMC: 11876407. DOI: 10.3389/frtra.2024.1496702.

Tigecycline-Based Regimens for Complicated Urinary Tract Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria: Case Series.

Niculae C, Gorea M, Tirlescu L, Matoru R, Hristea A Cureus. 2024; 16(7):e65617.

PMID: 39205739 PMC: 11350394. DOI: 10.7759/cureus.65617.

Isolation and Characterization of a Novel Phage and Its Combined Effect with Tigecycline in Controlling Multidrug-Resistant -Associated Skin and Soft Tissue Infections.

Wintachai P, Surachat K, Singkhamanan K Viruses. 2022; 14(2).

PMID: 35215788 PMC: 8878389. DOI: 10.3390/v14020194.

Role of Tigecycline for the Treatment of Urinary Tract Infections.

Wu G, Abraham T, Saad N J Pharm Technol. 2021; 30(3):87-92.

PMID: 34860885 PMC: 5990139. DOI: 10.1177/8755122513519332.

Efficacy and safety of tigecycline for complicated urinary tract infection: a systematic review.

Liu Y, Le K, Shi H, Zhang Z, Cui M, Zhong H Transl Androl Urol. 2021; 10(1):292-299.

PMID: 33532318 PMC: 7844507. DOI: 10.21037/tau-20-959.

References

Anthony K, Fishman N, Linkin D, Gasink L, Edelstein P, Lautenbach E . Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis. 2008; 46(4):567-70. DOI: 10.1086/526775. View

Cai Y, Wang R, Liang B, Bai N, Liu Y . Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2010; 55(3):1162-72. PMC: 3067123. DOI: 10.1128/AAC.01402-10. View

Greenberg S, Reiser I, CHOU S, Porush J . Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med. 1993; 119(4):291-5. DOI: 10.7326/0003-4819-119-4-199308150-00007. View

Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N . Penetration of antimicrobial agents into the prostate. Chemotherapy. 2003; 49(6):269-79. DOI: 10.1159/000074526. View

Kanj S, Kanafani Z . Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011; 86(3):250-9. PMC: 3046948. DOI: 10.4065/mcp.2010.0674. View

Pitout J . Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs. 2010; 70(3):313-33. DOI: 10.2165/11533040-000000000-00000. View

Reid G, Grim S, Aldeza C, Janda W, Clark N . Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy. 2007; 27(8):1198-201. DOI: 10.1592/phco.27.8.1198. View

Nix D, Matthias K . Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation. J Antimicrob Chemother. 2010; 65(6):1311-2. DOI: 10.1093/jac/dkq116. View

Barbour A, Schmidt S, Ma B, Schiefelbein L, Rand K, Burkhardt O . Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet. 2009; 48(9):575-84. DOI: 10.2165/11317100-000000000-00000. View

10.

Senol S, Tasbakan M, Pullukcu H, Sipahi O, Sipahi H, Yamazhan T . Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J Chemother. 2010; 22(5):355-7. DOI: 10.1179/joc.2010.22.5.355. View

11.

Lim L, Ly N, Anderson D, Yang J, Macander L, Jarkowski 3rd A . Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy. 2010; 30(12):1279-91. PMC: 4410713. DOI: 10.1592/phco.30.12.1279. View

12.

Cunha B, McDermott B, Nausheen S . Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection. J Chemother. 2008; 19(6):753-4. DOI: 10.1179/joc.2007.19.6.753. View

13.

Geerlings S, van Donselaar-van der Pant K, Keur I . Successful treatment with tigecycline of two patients with complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother. 2010; 65(9):2048-9. DOI: 10.1093/jac/dkq224. View

14.

Michalopoulos A, Livaditis I, Gougoutas V . The revival of fosfomycin. Int J Infect Dis. 2011; 15(11):e732-9. DOI: 10.1016/j.ijid.2011.07.007. View

15.

Satlin M, Kubin C, Blumenthal J, Cohen A, Furuya E, Wilson S . Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother. 2011; 55(12):5893-9. PMC: 3232750. DOI: 10.1128/AAC.00387-11. View

16.

Cunha B . Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol. 2009; 47(5):1613. PMC: 2681882. DOI: 10.1128/JCM.00404-09. View

17.

Lipsky B, Byren I, Hoey C . Treatment of bacterial prostatitis. Clin Infect Dis. 2010; 50(12):1641-52. DOI: 10.1086/652861. View

18.

Krueger W, Kempf V, Peiffer M, Nagele U, Unertl K, Schroeder T . Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol. 2007; 46(2):817-20. PMC: 2238119. DOI: 10.1128/JCM.01340-07. View

19.

Drekonja D, Johnson J . Tigecycline treatment for urinary tract infections: case report and literature review. J Chemother. 2011; 23(3):168-70. DOI: 10.1179/joc.2011.23.3.168. View

20.

Gallagher J, Rouse H . Tigecycline for the treatment of Acinetobacter infections: a case series. Ann Pharmacother. 2008; 42(9):1188-94. DOI: 10.1345/aph.1L171. View